Waheed Jamal, Boehringer Ingelheim’s head of cardio, renal and metabolic medicine
February 26, 2024 07:07 AM ESTUpdated February 27, 03:32 AM
R&D

Boehringer In­gel­heim un­veils mid-stage win for glucagon/GLP-1 can­di­date for MASH, kin­dling PhI­II plans

Reynald Castañeda

Deputy Editor

Boehringer In­gel­heim said on Mon­day that its “dou­ble G” meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH) drug de­liv­ered pos­i­tive topline re­sults in a Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times